LT3872095T - Daugiaspecifiniai mutuoti antikūninų fab fragmentai - Google Patents

Daugiaspecifiniai mutuoti antikūninų fab fragmentai

Info

Publication number
LT3872095T
LT3872095T LTEP20168633.4T LT20168633T LT3872095T LT 3872095 T LT3872095 T LT 3872095T LT 20168633 T LT20168633 T LT 20168633T LT 3872095 T LT3872095 T LT 3872095T
Authority
LT
Lithuania
Prior art keywords
multispecific
fab fragments
antibody fab
mutated antibody
mutated
Prior art date
Application number
LTEP20168633.4T
Other languages
English (en)
Inventor
Jean Kadouche
Jean-Pierre Mach
Olivier Michielin
Vincent Zoete
Justyna IWASZKIEWICZ
Martine Cerutti
Sylvie CHOBLET
Josée GOLAY
Original Assignee
Centre National De La Recherche Scientifique (Cnrs)
University Of Lausanne
Azienda Socio-Sanitaria Territoriale Papa Giovanni Xxiii
Jean Kadouche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique (Cnrs), University Of Lausanne, Azienda Socio-Sanitaria Territoriale Papa Giovanni Xxiii, Jean Kadouche filed Critical Centre National De La Recherche Scientifique (Cnrs)
Publication of LT3872095T publication Critical patent/LT3872095T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
LTEP20168633.4T 2011-07-07 2012-07-06 Daugiaspecifiniai mutuoti antikūninų fab fragmentai LT3872095T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305872A EP2543680A1 (en) 2011-07-07 2011-07-07 Multispecific mutated antibody Fab fragments

Publications (1)

Publication Number Publication Date
LT3872095T true LT3872095T (lt) 2024-03-12

Family

ID=44904654

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP20168633.4T LT3872095T (lt) 2011-07-07 2012-07-06 Daugiaspecifiniai mutuoti antikūninų fab fragmentai
LTEP12748555.5T LT2729499T (lt) 2011-07-07 2012-07-06 Multispecifiniai mutuoti antikūno fab fragmentai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP12748555.5T LT2729499T (lt) 2011-07-07 2012-07-06 Multispecifiniai mutuoti antikūno fab fragmentai

Country Status (18)

Country Link
US (4) US9631031B2 (lt)
EP (4) EP2543680A1 (lt)
JP (1) JP6305332B2 (lt)
KR (1) KR102095886B1 (lt)
CN (1) CN103797033B (lt)
CA (2) CA3099509C (lt)
CY (1) CY1123484T1 (lt)
DK (2) DK2729499T3 (lt)
ES (1) ES2816701T3 (lt)
FI (1) FI3872095T3 (lt)
HR (2) HRP20240005T1 (lt)
HU (1) HUE051620T2 (lt)
LT (2) LT3872095T (lt)
MX (1) MX351418B (lt)
PL (1) PL2729499T3 (lt)
PT (2) PT2729499T (lt)
SI (1) SI2729499T1 (lt)
WO (1) WO2013005194A2 (lt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
MX362705B (es) 2012-05-10 2019-02-01 Bioatla Llc Anticuerpos monoclonales multiespecíficos.
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2925785A4 (en) * 2012-11-28 2016-11-16 Zymeworks Inc MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
DK3107938T3 (da) 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CN104371974B (zh) * 2014-10-24 2017-03-22 杭州阿诺生物医药科技股份有限公司 一种自体外周血淋巴细胞cik的培养方法
EP3212231B1 (en) * 2014-10-27 2021-04-28 Agency For Science, Technology And Research Anti-tim-3 antibodies
AU2016252773B2 (en) * 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
MY192202A (en) * 2015-10-02 2022-08-06 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
US11161915B2 (en) 2015-10-08 2021-11-02 Zymeworks Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
AU2016381605A1 (en) 2015-12-28 2018-07-12 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
DK3433273T3 (da) 2016-03-25 2022-02-14 Biomunex Pharmaceuticals Binding af molekyler til cd38 og pd-l1
CN109563166B (zh) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
KR20170123849A (ko) * 2016-04-29 2017-11-09 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
EP3489262A4 (en) * 2016-07-19 2020-07-08 Ibentrus, Inc. SPECIFIC PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
CN108264557B (zh) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
CN108264562B (zh) * 2016-12-30 2021-08-10 惠和生物技术(上海)有限公司 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用
CN110520444A (zh) 2017-01-09 2019-11-29 拜奥穆尼克斯制药 用于制备多特异性抗体的多肽接头
BR112019019998A2 (pt) * 2017-03-27 2020-04-28 Biomunex Pharmaceuticals anticorpos multiespecíficos estáveis
MX2019011770A (es) 2017-04-03 2020-01-09 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
CN116375876A (zh) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
FR3072686B1 (fr) 2017-10-25 2021-10-22 Centre Nat Rech Scient Systeme d'expression baculovirus
CA3084398A1 (en) * 2018-01-15 2019-07-18 I-Mab Biopharma Us Limited Modified c.kappa. and ch1 domains
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
AU2019412561A1 (en) * 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
WO2022219076A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
CN114106192A (zh) * 2021-12-20 2022-03-01 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
WO2023166098A1 (en) 2022-03-02 2023-09-07 Biomunex Pharmaceuticals Bispecific antibodies binding to her-3 and to either her-2 or egfr

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
DE4419399C1 (de) * 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
LT2857516T (lt) * 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
US20090182127A1 (en) * 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
WO2009015518A1 (fr) 2007-08-02 2009-02-05 Essence Technology Solution, Inc. Procédé de communication pour fournir un téléphone multimode voix sur ip dans un dispositif mobile
CA2709847C (en) * 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
PT2310970E (pt) * 2008-06-20 2013-07-26 Massachusetts Inst Technology Métodos de identificação de regiões de ligação macromolecular e de regiões predispostas à agregação nas proteínas e suas utilizações
CN102625813A (zh) * 2008-06-20 2012-08-01 诺华公司 具有降低的聚集的免疫球蛋白
CA2736408A1 (en) * 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-egfr/anti-igf-1r antibodies
JP2012525149A (ja) * 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
PL2430051T3 (pl) 2009-05-14 2017-04-28 Institut National de la Santé et de la Recherche Médicale Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments

Also Published As

Publication number Publication date
HUE051620T2 (hu) 2021-03-29
PL2729499T3 (pl) 2021-03-08
EP3872095B1 (en) 2023-10-25
HRP20240005T1 (hr) 2024-03-29
EP4252772A3 (en) 2023-11-01
KR102095886B1 (ko) 2020-04-02
CA2841039C (en) 2021-04-20
EP2729499A2 (en) 2014-05-14
JP2014522644A (ja) 2014-09-08
US20210040235A1 (en) 2021-02-11
CN103797033A (zh) 2014-05-14
CA2841039A1 (en) 2013-01-10
WO2013005194A3 (en) 2013-04-18
EP2543680A1 (en) 2013-01-09
US10815310B2 (en) 2020-10-27
LT2729499T (lt) 2020-08-25
CA3099509C (en) 2022-10-25
US11945879B2 (en) 2024-04-02
MX2014000234A (es) 2014-09-04
PT3872095T (pt) 2024-01-09
DK3872095T3 (da) 2024-01-08
FI3872095T3 (fi) 2024-01-09
KR20140074274A (ko) 2014-06-17
CA3099509A1 (en) 2013-01-10
EP4252772A2 (en) 2023-10-04
EP2729499B1 (en) 2020-04-29
CY1123484T1 (el) 2022-03-24
HRP20201191T1 (hr) 2020-11-13
US20200385490A1 (en) 2020-12-10
MX351418B (es) 2017-10-13
CN103797033B (zh) 2016-12-07
DK2729499T3 (da) 2020-08-03
WO2013005194A2 (en) 2013-01-10
SI2729499T1 (sl) 2020-12-31
ES2816701T3 (es) 2021-04-05
US20180022829A1 (en) 2018-01-25
JP6305332B2 (ja) 2018-04-04
US9631031B2 (en) 2017-04-25
EP3872095A1 (en) 2021-09-01
PT2729499T (pt) 2020-08-03
US20140242076A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
FI3872095T3 (fi) Multispesifisiä mutatoituja fab-vasta-ainefragmentteja
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
ZA201400768B (en) Interleukin-31 monoclonal antibody
HK1197182A1 (en) Cancer immunotherapy
EP2722343A4 (en) ANTI-ERBB3 ANTIBODIES
SI2794658T1 (sl) Bispecifična molekula protitelesa
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
EP2922874A4 (en) BISPECIFIC ANTIBODIES
IL229618B (en) An isolated antibody that binds fcrn
EP2686349A4 (en) METHODS OF ANTIBODY SCREENING
TWI563004B (en) Anti-hxcr1 antibody
GB201120860D0 (en) Cancer immunotherapy
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201116342D0 (en) Antigen combinations
HK1175486A1 (zh) 抗腫瘤壞死因子α的人源化抗體